| Drug NDC: | 83021-750 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Anubismed |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Ha Hyaluronic |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Anubis Cosmetics Sl |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Cream |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | 1,2-HEXANEDIOL - .198 g/50mL ALLANTOIN - .05 g/50mL ALOE VERA LEAF - 2.5 g/50mL BUTYLATED HYDROXYTOLUENE - .0535 g/50mL C12-20 ACID PEG-8 ESTER - 2.25 g/50mL CAPRYLYL GLYCOL - .198 g/50mL CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE - .25 g/50mL CETEARYL ETHYLHEXANOATE - 1.75 g/50mL CETYL ALCOHOL - .0038 g/50mL DECYL OLEATE - 1.9996 g/50mL Load more... DIMETHICONE - .25 g/50mL FRAGRANCE 13576 - .225 g/50mL GLYCERIN - .4975 g/50mL GLYCERYL MONOSTEARATE - .875 g/50mL GLYCERYL STEARATE SE - 1.5 g/50mL IMIDUREA - .15 g/50mL MEDIUM-CHAIN TRIGLYCERIDES - 1.5 g/50mL OCTINOXATE - 3.4965 g/50mL OXYBENZONE - 2 g/50mL PROPYLENE GLYCOL - 1.996 g/50mL TOCOPHEROL - .0004 g/50mL TROLAMINE - .3 g/50mL TROPOLONE - .004 g/50mL WATER - 27.4065 mL/50mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | TOPICAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 17 Oct, 2022 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 14 May, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Application Number: | M016 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | ANUBIS COSMETICS SL |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000010282 N0000185370 N0000175629 N0000184306 N0000185001 M0000728 M0009417 N0000185508 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | TR046Y3K1G 344S277G0Z ZY81Z83H0X 1P9D0Z171K 9M7A3K4339 00YIU5438U 0A5MM307FC 9M64UO4C25 936JST6JCN ZGR06DO97T Load more... 92RU3N3Y1O 5EM498GW35 PDC6A3C0OX 230OU9XXE4 FCZ5MH785I M629807ATL C9H2L21V7U 4Y5P7MUD51 95OOS7VE0Y 6DC9Q167V3 R0ZB2556P8 9O3K93S3TK 7L6DL16P1T 059QF0KO0R |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class EPC: | Non-Standardized Chemical Allergen [EPC] Standardized Chemical Allergen [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class PE: | Skin Barrier Activity [PE] Increased Histamine Release [PE] Cell-mediated Immunity [PE] Increased IgG Production [PE] |
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. | |
| Pharmacologic Class CS: | Allergens [CS] Glycerol [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Allergens [CS] Cell-mediated Immunity [PE] Glycerol [CS] Increased Histamine Release [PE] Increased IgG Production [PE] Non-Standardized Chemical Allergen [EPC] Skin Barrier Activity [PE] Standardized Chemical Allergen [EPC] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 83021-750-50 | 50 mL in 1 JAR (83021-750-50) | 17 Oct, 2022 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.